Expert: Professor Michael Mauro Leader of the Myeloproliferative Neoplams Program at the Memorial Sloan Kettering Cancer Centre / Professor of Clinical Medicine at the Weill Cornell Medical College, New York (USA)

Program:
Overview of significant clinical aspects presented during the meeting, including:

• 00:51 ASCIMINIB
  
  • ASCEND Study
  • ASC4More Study
• 04:49 Olverembatinib
  • Olverembatinib in patients with T315I mutation
  • Olverembatinib in resistant CML
• 08:32 Vodobatinib phase 1 Study
• 11:35 Dasatinib, PEG-INF, Ponatinib
  • Long-term low-dose Dasatinib frontline in CML
  • ENDURE Study: PEG-INF after discontinuation
  • OPTIC Trial: Optimization of Ponatinib in different doses
• 18:28 Non-ABL Myeloid Mutations
• 22:16 TFR, Race/ethnicity, AP-CML and BC-CML
  • TFR-PRO Observational Study
  • Survival by race/ethnicity
  • 2nd generation TKI vs Imatinib in AP-CML
  • BC-CML Registry

If you have any questions or comments to the speaker, please email info@cml-foundation.org.